EXAS News & Events

Exact Sciences (EXAS) announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (ABT) at the special meeting of stockholders. Subject to the satisfaction or waiver of the remaining conditions to closing, the transaction is expected to close before the end of the second calendar quarter of 2026.

Reports Q4 revenue $878M, consensus $860.76M. "In 2025 the Exact Sciences team delivered on our mission by screening more people than ever before, helping guide more personalized treatment decisions, and successfully launching three new tests," said Kevin Conroy, Chairman and CEO of Exact Sciences. "These defining milestones show what the Exact Sciences team can achieve through a relentless focus on our mission and a dedication to improving the lives of patients. As we look to the future, momentum continues to build. Our core products are driving strong growth, our portfolio is expanding, and we are uniquely positioned to drive lasting change in the way cancer is found and treated globally."

Exact Sciences celebrates the passage of federal legislation that establishes a pathway to enable Medicare coverage for multi-cancer early detection , or MCED, tests. "By aligning public policy with scientific innovation and patient need, this legislation represents a critical step toward addressing that unmet need and expanding access to this emerging technology for millions of Medicare beneficiaries," the company stated. "It's a historic day in the fight against cancer. We are deeply grateful to lawmakers, especially Representatives Terri Sewell and Jodey Arrington, patient advocates, and all those who fought tirelessly for this groundbreaking legislation. Most importantly, we are thrilled for the countless individuals whose lives will be impacted by these tests, potentially giving them more opportunities to celebrate birthdays, anniversaries, and precious moments with their loved ones," said Kevin Conroy, chairman and CEO of Exact Sciences.